Overview

Phase 2, Efficacy, Safety, and Pharmacokinetics Study of Two INV-202 Doses in Patients With Diabetic Kidney Disease

Status:
Not yet recruiting

Trial end date:
2024-07-24

Target enrollment:

Participant gender:

Summary

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus

Phase:

Phase 2

Details

Lead Sponsor:

Inversago Pharma Inc.

Collaborator:

Worldwide Clinical Trials